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The tumor microenvironment is the battle-
ground of pro- and anti-tumor factors. On 
the tumor’s side, epithelial–mesenchymal 
transition (EMT) and tumor budding is 
the histomorphologic signature of aggres-
sive disease. On the host’s side, T-effector 
cell infiltrates are the hallmark of an active 
anti-tumoral immune defense. These mor-
phological features can be measured by 
the histopathologist and represent impor-
tant novel histomorphological prognostic 
factors in colorectal cancer (CRC).
The tumor microenvironment in 
colorectal cancer
On the battleground, the picket lines cor-
relate to the resources available to each war-
ring party that are strategically employed 
in the terrain at stake. In the tumor micro-
environment, a constantly growing mass of 
malignant cells infiltrates the locoregional 
tissue, reaching the opportunity for sys-
temic spread when lymphovascular spaces 
are breached. Recent studies highlight that 
epithelial tumors undergo mesenchymal 
transition in the tumor microenvironment, 
allowing dissociative growth, migration 
and lysis of stromal components [1]. It is 
likely that single tumor cells in the tumor 
microenvironment permeate vessels and 
may be the seed for distant metastatic dis-
ease, which is the eventual cause of death 
for many cancer patients [2]. This hypothe-
sis is supported by data demonstrating stem 
cell-like features in cells undergoing EMT 
[3], and evidence of a reverse process of 
mesenchymal–epithelial transition in sites 
of metastasis [2]. In CRC, the visible snap-
shot of cells undergoing EMT is the pres-
ence of single cells or small clusters of up 
to five cells in the tumor stroma ahead of 
the invasive front, termed tumor buds [4].
Infiltrating tumor buds and the main 
tumor are subject to constant immuno-
selective pressure from the adaptive anti-
tumor immunity, which recognizes aberrant 
antigen profiles, and is capable of mounting 
an efficient antitumoral immune response. 
Strong experimental and translational 
evidence suggests that efficient immune 
“The balance of pro- and anti-tumor factors 
may ... define whether local tumor progression 
will result in breach of the vascularity and 
systemic spread of disease or whether the 
neoplastic cell population can be contained by 
an active anti-tumoral effector and memory 
T-cell response.”
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rejection of a tumor shows a characteristic, rep-
licable profile with highly conserved patterns 
between different patients and even different 
tumor types [5]. Recently, this host-related fac-
tor has been made accessible for histopathologic 
quantification through the development of the 
‘immunoscore’ [6]. The use of the immunoscore 
in CRC has demonstrated two central findings [7]. 
First, patients with a strong in situ immune reac-
tion to CRC have infrequent metastatic spread of 
disease and a significantly improved disease-free 
and overall survival. Second, the prognostic value 
of the immunoscore may offer superior discrimi-
natory power to TNM staging and is independent 
of the anatomic extent of the tumor.
Budding: the tumor-related factor
Tumor budding was first described by Jeremy 
Jass in 1986, and has been well characterized as 
a reproducible and frequent feature of CRC with 
a highly aggressive clinical course [8]. The pres-
ence of tumor buds in CRC is an independent 
predictive factor of local recurrence of disease, 
lymphovascular invasion, nodal and distant 
metastasis, and poor disease-specific survival [9]. 
This independent predictive information may be 
of decisive value in central clinical settings. First, 
the presence of tumor budding in endoscopically 
removed malignant polyps may be an indicator 
of locoregional spread of disease requiring seg-
mental resection [10]. Second, the presence of 
tumor budding may identify patients who follow 
an aggressive clinical course in locally advanced, 
node-negative, stage 2 disease who may profit 
from chemotherapy to prevent distant disease 
recurrence [11]. Third, tumor budding may repre-
sent a novel histomorphological prognostic factor 
for application in biopsy samples, allowing effec-
tive risk stratification of CRC patients at the time 
of histopathological confirmation of diagnosis 
[12]. Consequently, the value of tumor buds in the 
tumor microenvironment has been recognized 
as an additional prognostic factor by WHO and 
the Union for International Cancer Control [13].
Translational research suggests that tumor 
budding at the invasive front of CRC is often 
found in tumors with activation of EMT-related 
signaling pathways; an increased expression of 
TGF-β or loss of cell adhesins such as E-cadherin 
or syndecan-1 frequently accompanies the pres-
ence of tumor buds at the invasive front [9]. 
Furthermore, the presence of tumor buds is 
often detected in tumors with an increased 
capability for stromal degradation, characterized 
by increased expression of metallo proteinases, 
cathepsin B or urokinase receptor [9]. Tumor buds 
themselves frequently exhibit ‘pseudopodia-like’ 
cytoplasmic protrusions, which may be formed 
during the process of migration [14]. Interestingly, 
tumor buds also overexpress proteins related to 
stromal degradation as further evidence of their 
migratory potential [15]. Putative stem cell fea-
tures have been linked to the protein expression 
of ABCG5 and EPCAM in tumor buds, which 
may allow the seeding of distant sites once the 
tumor vasculature is permeated [16].
The fact that tumor budding can be quanti-
tated, shows powerful independent prognostic 
value and is related to aggressive disease biology 
suggests that scoring tumor buds should become 
part of the standard pathological assessment of 
CRC. Much like the Gleason score for prostate 
cancer, or the Bloom–Richardson–Elston score 
for breast cancer, the prognostic power of tumor 
budding could therefore be harnessed for daily 
diagnostic practice in gastrointestinal pathology. 
Central to the establishment of a novel predictive 
factor is the ease of application and interobserver 
reproducibility; substantial evidence suggests 
that scoring tumor buds in a clearly defined area 
is superior to the qualitative, subjective assess-
ment of tumor budding ‘intensity’ in terms of 
reproducibility and predictive value for adverse 
outcome [17]. Furthermore, tumor buds can be 
assessed in conventional hematoxylin and eosin-
stained slides but scoring can be facilitated by 
using pan-cytokeratin immunohisto chemistry 
[17]. As additional prognostic markers are highly 
valuable for therapy stratification, definite con-
sensus on the optimal method for assessment 
has to be reached urgently to carry this powerful 
prognostic factor into practice.
T-cell infiltrates: the host-related 
factor
According to the TNM classification of CRC 
specimens, we currently focus on the anatomic 
extension of the tumor itself for prognostication 
[13]. Even though well proven, this approach does 
not take any characteristics of the host response 
to the cancer into consideration. In particular, 
no measure of the antitumoral immune response 
is provided in standard histopathologic assess-
ment of CRC. Yet, strong evidence suggests 
that the activity of the antitumoral immune 
defense plays a major role for survival outcome 
of CRC patients [6,7]. However, no immune-
based prognostic factors have been established 
“...definite consensus on 
the optimal method for 
assessment has to be 
reached urgently to 
carry this powerful 
prognostic factor into 
practice.”
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in clinical practice since the first publication 
on intra tumoral immune infiltrates in CRC 
by Jass in 1986 [18]. In fact, we may have spent 
25 years of looking preferentially at one side of 
the histopathologic picture of CRC.
This may soon change. It is now recognized 
that the presence of intra- and peri-tumoral 
CD8+ cytotoxic and CD45RO+ memory T lym-
phocytes are characteristic of an inflamed tumor 
microenvironment and active immune rejection 
by the host. A new, possibly transformational 
approach has been developed in CRC research 
that emphasizes the role of the tumor–host inter-
action and gauges the activity of the antitumoral 
immune defense [6]. The so-called ‘immuno-
score’ allows histologic quantification of tumor 
infiltrating immune cells in the tumor center and 
the tumor margins [6,7]. A substantial number 
of retrospective clinical trials were published 
over the last decade demonstrating that in situ 
analysis of immune cell infiltrates in any region 
of CRC carries independent prognostic value for 
the patient. In fact, immune cells within tumor 
samples were found to be a better predictor of 
patient survival than the TNM system [7]. This 
may seem surprising, but it should be noted that 
an increased frequency and activation of effec-
tor T cells in the tumor microenvironment is 
linked to the complex process of an active anti-
tumoral defense. In these terms, an inflamed 
tumor microenvironment is characterized by 
STAT-1/IRF1/IRF5 activity, inflammatory Th1-
based cytokine expression and presence of T-cell 
attractants (CXCR3 and CCR5 ligands) [5]. This 
intricate modulation of the tumor microenviron-
ment converges in the presence of intratumoral 
and stromal effector T cells, which can then be 
quantified by the histopathologist.
As with tumor budding, the ease of assess-
ment and reproducibility of the immunoscore 
will play a central role for use in daily diag-
nostics. In an elegant approach, standardized 
software applications have been developed to 
allow objective and reproducible assessment of 
immune cell infiltrates [7]. Furthermore, inter-
national collaborative efforts are currently under 
way to validate the immunoscore in CRC in a 
large multinational, retrospective study [6].
Future perspective
The tumor microenvironment holds two prom-
ising prognostic factors that may allow detailed 
assessment of the balance of tumor growth and 
host defense. Based on continuous efforts of 
CRC researchers, an integration of both factors 
into daily diagnostic practice may seem plausible 
within the near future. The balance of pro- and 
anti-tumor factors may therefore define whether 
local tumor progression will result in breach of 
the vascularity and systemic spread of disease 
or whether the neoplastic cell population can 
be contained by an active anti-tumoral effec-
tor and memory T-cell response. Furthermore, 
combined assessment of the histomorphological 
features of the tumor–host interface may allow 
visual integration of the biological aggressiveness 
of disease and the strength of the anti tumoral 
immune defense in an ‘attacker–defender’ 
approach [19]. Consequently, prognostication 
based on both tumor budding as a tumor-
related factor and the immune infiltrates as a 
host-related factor could represent a promising 
translational approach for future studies.
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